Global Immunotherapy for Neuroblastoma Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Immunotherapy for Neuroblastoma Market 2023 by Company, Regions, Type and Application, Forecast to 2029

According to our (Global Info Research) latest study, the global Immunotherapy for Neuroblastoma market size was valued at USD 46 million in 2022 and is forecast to a readjusted size of USD 63 million by 2029 with a CAGR of 4.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.

This report is a detailed and comprehensive analysis for global Immunotherapy for Neuroblastoma market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Immunotherapy for Neuroblastoma market size and forecasts, in consumption value ($ Million), 2018-2029

Global Immunotherapy for Neuroblastoma market size and forecasts by region and country, in consumption value ($ Million), 2018-2029

Global Immunotherapy for Neuroblastoma market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029

Global Immunotherapy for Neuroblastoma market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Immunotherapy for Neuroblastoma

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Immunotherapy for Neuroblastoma market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals and Baxter Healthcare, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Immunotherapy for Neuroblastoma market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Dinutuximab
Naxitamab
Other

Market segment by Application
Hospital
Clinic
Other

Market segment by players, this report covers
United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Immunotherapy for Neuroblastoma product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Immunotherapy for Neuroblastoma, with revenue, gross margin and global market share of Immunotherapy for Neuroblastoma from 2018 to 2023.

Chapter 3, the Immunotherapy for Neuroblastoma competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Immunotherapy for Neuroblastoma market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Immunotherapy for Neuroblastoma.

Chapter 13, to describe Immunotherapy for Neuroblastoma research findings and conclusion.